• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the May 2, 2011 Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 1.46MB)
 
Addendum to the FDA Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 80KB)
 
Errata (1) to the FDA Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 11KB)
 
Errata (2) to the FDA Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 82KB)
 
 
Lantheus Medical Imaging, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Lantheus Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 873KB)
 
 
GE Healthcare
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
GE Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 903KB)
 
 
Bracco Diagnostics, Inc
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Bracco Briefing Information for the May 2, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (PDF – 683KB)